Navigation Links
Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application
Date:7/11/2014

SARASOTA, Fla., July 11, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), an emerging biotechnology company, today announced that the Food and Drug Administration ("FDA"), has notified the Company that the agency will provide comments on RCP's Investigational New Drug ("IND") application before granting the Company permission to start its clinical trial in the US.

Dr. Chris Chapman, RCP's President, commented, "We appreciate the agency's review and comments on our IND. When we receive the agency's official comments and/or recommendations, we will respond expeditiously. We look forward to moving this important product through the regulatory process."

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical dietary supplements products, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices and the outcome of the ongoing investigations as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2013 filed on March 17, 2014.  We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

About Rock Creek Pharmaceuticals, Inc.

Rock Creek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for inflammatory conditions, clinical immunology, neurological disease and behavioral health.  Additionally, through its subsidiary RCP Development, the Company is engaged in the manufacturing and sale of nutraceutical dietary supplements designed to promote maintenance of a healthy metabolism and lifestyle. 

For more information, visit: http://www.rockcreekpharma.com

Logo - http://photos.prnewswire.com/prnh/20140711/126408

CONTACT:
Ted Jenkins
Vice President, Corporate Strategy, Development, Investor Relations
Rock Creek Pharmaceuticals
tjenkins@rockcreekpharma.com

 


'/>"/>
SOURCE Rock Creek Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. AMG Medical Inc. Selects Saddle Creek for Multichannel Fulfillment
2. A Forever Recovery Battle Creek, MI: Increasing Recreational Drug Use in Colleges Creates Risk for Addictions
3. Creekridge Capital Continues Vendor Growth within Technology
4. Star Scientific and Rock Creek Pharmaceuticals Report on the Beneficial Nutritional Effects of Anatabine in an Animal Model of Ulcerative Colitis
5. Creekridge Capital Announces Record Volume
6. Creekridge Capital Adds Revolving Credit Specialist
7. Creekridge Capital Expands Healthcare Sales Team
8. Creekridge Capital Launches Vendor Sales Training Program
9. Creekridge Capital Grows Healthcare Sales Team
10. Creekridge Breaks Monthly and Quarterly Volume Records
11. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... 30, 2016 Eye expert s ... babies to seek an eye examination ...   Moorfields Eye Hospital Dubai, the first ... London , has identified premature babies as a special concern ... their particular vulnerability to retinopathy of prematurity (ROP). ROP is a ...
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharma company focused on the highly lucrative ... a substantial pipeline of potential first-in-class or best-in-class ... are in development with strategic partners. HCM,s profitable ... fast-growing domestic market. We expect progress of the ...
(Date:5/26/2016)... , May 26, 2016 According to ... Waste Management Market - U.S. Industry Analysis, Size, Share, Growth, ... market in the U.S. was valued at US$ 5.89 Bn ... of 3.4% from 2015 to 2023 to reach US$ 7.99 ... of current and emerging needle free drug delivery devices and ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... ... Houston Healthconnect’s (Healthconnect) regional health information exchange, which enables physicians at SJMC’s two ... their patients from other participating organizations in the exchange. SJMC’s membership in the ...
(Date:5/31/2016)... ... May 31, 2016 , ... CallTrackingMetrics's ... advertising campaigns, to monitor the performance of sales and support staff, and to ... revenue. The software allows customers to record, transcribe, route, document, and report on ...
(Date:5/31/2016)... ... ... The Global Wellness Summit (GWS), an annual conference for international ... travel, spa and beauty in Europe. The organization asked its partner experts in Europe ... researchers - to forecast where wellness is headed in Europe. Predictions range from European ...
(Date:5/31/2016)... ... 2016 , ... Interest is on the rise for using the CRISPR-Cas9 system ... for RNAi hit validation. A key reason may be that high-throughput synthesis—combined with a ... RNA (crRNA) collections in arrayed formats. , Arrayed crRNA screens have ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Dr. Charles A. ... Dentistry of New Jersey in the class of 1986, where he graduated in the ... at his current location in Livingston since 1989. He has been a member in ...
Breaking Medicine News(10 mins):